More Evidence Your Doctor's Working Harder Than Ever
The latest evidence of this trend is a report from Vizient's KaufmanHall consulting firm that shows net patient revenue per provider rose 4% to $404,116 in the second quarter of this year compared to $389,040 in the same period a year ago. Meanwhile, per-physician work relative value units (wRVUs), a key measure of physician productivity, rose 6% in the second quarter compared to the year-ago period.
'Physician productivity rose,' the KaufmannHall report shows. 'Corresponding increases in revenue and expenses indicate that physicians are working more.'
The report comes amid an intensifying shortage of physicians seeing more and more patients whose healthcare needs are greater. Part of this is related to demographics as baby boomers age but the main driver of compensation and related productivity is physicians are simply busier and there aren't enough of them.
The Association of American Medical Colleges says the United States will face a physician shortage of up to 86,000 physicians by 2036, according to a report the group released last year though a bipartisan group of U.S. Senators is pushing legislation to lift a cap on Medicare funding for residencies. Similar legislation has been proposed in the U.S. House of Representatives.
The KaufmanHall report, which is based on data from more than 200,000 employed physicians and advanced practice providers in more than 100 specialties, follows similar reports earlier this year on physician compensation and productivity.
The American Medical Group Association (AMGA) 2025 Medical Group Compensation and Productivity Survey, which showed a 4.9% compensation increase across its entire dataset, said work relative value units (wRVUs) increased 1.5% overall and that often correlates to increase in patient visits, which grew by 2.3%.
'We are at this tipping point,' AMGA Consulting's chief operating officer Mike Coppola said in an interview earlier this year. 'You cannot keep driving compensation increases through productivity. Volume is being driven on the backs of physicians and that is hard to sustain.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
UnitedHealth Stock Soars as Warren Buffett's Berkshire Hathaway Discloses $1.57B Stake
UnitedHealth Group (UNH) stock has been a major underperformer in 2025, with UNH down nearly 50% year-to-date amid rising medical costs, regulatory scrutiny, and a Department of Justice investigation into billing practices. However, the company received a major vote of confidence after the closing bell today, when Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) disclosed a substantial new position in UnitedHealth totaling 5.04 million shares, valued at approximately $1.57 billion. As a result, UNH stock has surged over 8% in after-hours trading. That puts UnitedHealth on pace to challenge its overhead 50-day moving average in Friday's session. The shares haven't closed above this descending trendline since mid-April. More News from Barchart 1 'Strong Buy' Dividend Stock to Buy to Protect Your Portfolio After Hitting 30th 52-Week Low, Is Adobe Too Cheap to Ignore? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Why Did Buffett Buy UNH Stock? Valued at $246 billion by market cap, UnitedHealth maintains its position as America's largest health insurer. Despite operational headwinds, the company has maintained its quarterly dividend of $2.21 per share. UNH now yields approximately 3.25%, demonstrating its commitment to shareholder returns and financial stability. Plus, after its steep selloff this year, the stock's current valuation of 11.5 times projected 2027 earnings is significantly below historical averages - suggesting the market may be pricing in an overly pessimistic outlook. What's the Forecast for UNH Stock? Management anticipates a return to growth in 2026 as premium pricing adjustments take effect to offset higher medical costs, particularly in Medicare Advantage plans. Recent trading sessions have shown signs of positive momentum for UNH, with shares rising approximately 11% over the past 5 days as part of a broader rotation into beaten-down healthcare stocks - though the name remains well off its previous highs. Along with Buffett, Wall Street maintains a generally positive outlook on the beaten-down stock, which has a consensus 'Moderate Buy' recommendation. JPMorgan recently reiterated a 'Buy' rating and set a $310 price target for UNH, suggesting about 14% expected upside potential from Thursday's close. This article was created with the support of automated content tools from our partners at Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever. On the date of publication, Elizabeth H. Volk did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. OS Therapies Contact Information:Investor RelationsHarrison Seidner, PhDWaterSeid PartnersOSTX@ Public RelationsStephanie ChenElev8 New Mediastephanie@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Costco says it won't sell mifepristone abortion pill
Costco will not sell the abortion pill mifepristone at its pharmacy locations, the shopping club told CBS News. The wholesaler said its decision not to sell the prescription medication was based on a "lack of demand from our members and other patients." "They generally have the drug dispensed by their medical providers," Costco said in a statement to CBS News. Costco's position on the abortion pill, which was first reported by Bloomberg, was praised by a conservative religious coalition, called the Alliance Defending Freedom (ADF), an anti-abortion advocacy group that had urged Costco not to sell mifepristone. "We applaud Costco for doing the right thing by its shareholders and resisting activist calls to sell abortion drugs," ADF's legal counsel Michael Ross said in a statement Thursday. "Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries." Mifepristone, first approved by the Food and Drug Administration in 2000, is part of a two-step regimen with misoprostol used to end a pregnancy through 10 weeks. It is used in over half of all abortions in the U.S., according to research from the Guttmacher Institute. Passenger arrested after allegedly causing disturbance midair and forcing flight to divert Tropical Storm Erin expected to become a major hurricane When could Tropical Storm Erin become a hurricane? Solve the daily Crossword
